News

Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration and diabetic macular edema.

Surgeon expects more MIGS, less trabeculectomy.

The company’s CT Lucia 621P monofocal IOL enables surgeons to treat a wide range of cataract patients while supporting optimised visual outcomes.

Conducting a thorough financial examination may help clinicians to see their finances as clearly as their patients see the world after cataract surgery.

Dr Edmund Arthur shares his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.

Ophthalmology Times® talked with Roger Goldberg, MD, MBA, about macular leakage area in the YOSEMITE and RHINE trials comparing faricimab to aflibercept at this year's ARVO meeting.

The company’s CT Lucia 621P monofocal IOL enables surgeons to treat a wide range of cataract patients while supporting optimized visual outcomes.

Instead, vitamins C and E may actually be associated with a slightly increased risk of DED.

Ophthalmology Times® spoke with Carl Danzig, MD, FASRS, at the 2023 ARVO annual meeting to learn more about the post hoc analysis for the GATHER trials and the new data on the correlation between vision loss and GA growth.

Body mass index (BMI), central obesity, and the metabolic syndrome may be deciding risk factors in glaucoma.

Ophthalmology Times® talked with Jay Barth, MD, about the work at Ascidian Therapeutics and their research into developing a new way to administer gene therapy at this year's ARVO meeting.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, it was noted ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, SB15 demonstrates comparable efficacy, safety, immunogenicity, and pharmacokinetics profiles to reference aflibercept up to Week 56.

At the 2023 ARVO annual meeting in New Orleans, our on-site team caught up with T. Y. Alvin Liu, MD, to discuss predictive AI and its application in ophthalmology and screening of the eyes.

Deborah Ferrington, PhD, spoke with on our on-site team at the 2023 ARVO annual meeting in New Orleans about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium (RPE).

Eyevensys reported data showing the efficacy and durability of EYS809, a dual-gene plasmid in development for the treatment of wet age-related macular degeneration (AMD).

Under a compassionate use program, the topical application of B-VEC to the eye was well tolerated and patient showed significant improvement of visual acuity and complete corneal re-epithelization. The company presented data at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans.

In a poster presented at the Association for Research in Vision and Ophthalmology, authors Paul S. Kayne, PhD, Alison Obr, PhD, John H. Dodd, PhD, and Carl Spana, PhD, it was demonstrated that PL9588 reduces ocular pressure. Data provides further support for topical administration of melanocortins for ocular inflammation.

At ARVO in New Orleans, Luxa Biotechnology shared an update on the progress of a Phase 1/2a clinical trial evaluating transplantation of RPESC-RPE-4W to treat dry age-related macular degeneration (AMD).

Therapies to target geographic atrophy are in sight.

Francine Behar-Cohen, MD, PhD, presented the data at the Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans.

Dr T.Y. Alvin Liu talks about predictive AI and its uses in ophthalmology and screening of the eyes at this year's ARVO meeting.

Ophthalmology Times® talked with David Eveleth, MD, CEO and Founder of Trefoil Therapeutics about TTHX1114 in patients with Fuchs endothelial corneal dystrophy (FECD) undergoing Descemet’s Stripping Only (DSO) in combination with cataract surgery at this year's ARVO meeting.

Visual impairment is associated with hallucinations, depression, agitation, and psychosis in patients with dementia.

Researchers found in their analysis that visual impairment is associated with hallucinations, depression, agitation, and psychosis in patients with dementia, although, aging and comorbidities, among other factors, may be involved.

Grace Walther, first author of the study, described that lens centration on the eye may be beneficial for improving vision. Association for Research in Vision and Ophthalmology annual meeting.

Amir H. Kashani, MD, PhD, joined us to share insights from his presentation at the 2023 ARVO meeting on optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and other related dementias.

Amir H. Kashani, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and other related dementias.